Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 237-358-4 | CAS number: 13762-14-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Oral (OECD 423), rat: LD50: 2500 mg/kg bw (cut-off value)
Read-across from molybdenum substances:
Inhalation (OECD 403), rat: LD50 > the maximum attainable test concentration or > 5 mg/L air (RA from soluble molybdenum substances; limit tests)
Dermal (OECD 402), rat: LD50 > 2000 mg/kg bw (RA from soluble molybdenum substances; limit tests)
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 29 Mar - 27 Apr 2011
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP - Guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Secrétariat général du Groupe Interministeriel Des Produits Chimiques - DGCIS-SI - 12, rue Villiot, 75572 Paris cedex 12, France
- Test type:
- acute toxic class method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Elevage JANVIER (53940 Le Genest St Isle - France)
- Age at study initiation: 8 weeks
- Weight at study initiation: 180 - 201 g
- Fasting period before study: Food was removed at D-1 and then redistributed 4 h after test item administration
- Housing: by group of three in solid-bottomed clear polycarbonate cages with a stainless steel mesh lid; each cage contains sawdust bedding which was changed at least 2 times a week; each cage was installed in conventional air conditioned animal husbandry.
- Diet: ad libitum; M20-rat/mouse maintenance (made from the formulation EXTRALABO from PIETREMENT)
- Water: ad libitum; tap water from public distribution system (microbiological and chemical analyses carried out every six months by the IPL, Santé, Environnement Durables - Atlantique)
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19-25
- Humidity (%): 30-70
- Air changes (per hr): approx. 15
- Photoperiod (hrs dark / hrs light): 12/12 (19:00 to 7:00)/(7:00-19:00) - Route of administration:
- oral: gavage
- Vehicle:
- other: distilled water
- Details on oral exposure:
- VEHICLE
- Amount of vehicle (if gavage): 10 mL/kg bw
DOSAGE PREPARATION:
In the first and second steps of the study, 300 mg of the test item was weighed and distilled water was added to a 10 mL volumetric flask. The preparation was magnetically stirred to obtain a battle-grey solution, just before the administration.
In the third and fourth steps of the study, 2000 mg of the test item was weighed and distilled water was added to 10 mL volumetric flask. The preparation was magnetically stirred to obtain a battle-grey solution, just before the administration.
- Doses:
- 300 and 2000 mg/kg bw
- No. of animals per sex per dose:
- 6 (3 animals each in two steps)
- Control animals:
- yes
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: clinical observations were carried out daily; body weights were determined on D0 (just before administering the test substance), D2, D7 and D14
- Necropsy of survivors performed: yes - Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 2 500 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: LD50 cut-off according to OECD 423
- Mortality:
- 300 mg/kg bw dose group: no mortality (0/6)
2000 mg/kg bw dose group: death of one rat during the second step of the study on Day 6 (1/6)
2000 mg/kg bw
2 of 6 animals found dead during the study: one animal from step 1 died at 28 hours 55 minutes post-dose and one animal from step 2 died at 21 hours post-dose. - Clinical signs:
- other: 300 mg/kg bw dose group: no clinical signs related to the administration of the test item were observed. 2000 mg/kg bw dose group: animal found dead (1/6): a decrease in spontaneous activity and piloerection on Day 5 surviving animals (5/6): a decrease i
- Gross pathology:
- 300 mg/kg bw dose group: The macroscopical examination of the animals at the end of the study did not reveal treatment-related changes.
2000 mg/kg bw dose group:
animal found dead (1/6): The macroscopical examination of the dead animal revealed a thinning of forestomach and corpus; a red thickening of the distal part of the forestomach and red/greenish coloration of corpus, black liquid in the caecum and bright red coloration of the lungs.
surviving animals (5/6): The macroscopical examination of the animals at the end of the study did not reveal treatment-related changes. - Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- CLP: not classified
DSD: not classified
Reference
Table 1
Dose |
Toxicological results* |
Duration of clinical signs |
Time of death |
Mortality (%) |
Females |
||||
300 |
0/0/6 |
--- |
--- |
0 |
2000 |
1/2/6 |
Day 5 – Day 6 |
Day 6 |
16.7 |
LD50 = 2500 mg/kg bw (LD50 cut off-according to OECD 423) |
* first number = number of dead animals
second number = number of animals with clinical signs
third number = number of animals used
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 500 mg/kg bw
Additional information
The acute oral toxicity study has been performed according to OECD 423 (Colas, 2011). 6 female rats each received a single oral dose of 2000 mg/kg bw or 300 mg/kg bw cobalt molybdenum oxide. In the lower dosed group, all animals survived and no test substance-related clinical signs were observed. Macroscopical examination of the animals did not reveal treatment-related changes. One rat treated with 2000 mg/kg bw died on day 6. The day before, a decrease in spontaneous activity, piloerection and body weight was observed. The macroscopical examination of the dead animal revealed a thinning of forestomach and corpus; a red thickening of the distal part of the forestomach and red/greenish coloration of corpus, black liquid in the caecum and bright red coloration of the lungs. 1/5 of the surviving animals showed a decrease in spontaneous activity and piloerection, which appeared on days 5 and 6. The animal recovered a normal behaviour on day 7. The macroscopical examination of the surviving animals did not reveal treatment-related changes at the end of the study. The LD50 cut-off was determined as 2500 mg/kg bw cobalt molybdenum oxide.
There are no data available on acute toxicity via the inhalation or dermal route for cobalt molybdenum oxide. However, there are reliable data for soluble cobalt and molybdenum substances considered suitable for read-across using the analogue approach. For identifying hazardous properties of cobalt molybdenum oxide, the existing forms of cobalt molybdenum oxide at very acidic and physiological pH conditions are relevant for risk assessment of human health effects. Cobalt molybdenum oxide is a metal-organic salt, which is highly water soluble (~ 508 mg/L) and nearly completely dissociates in aqueous solutions. As it is expected that cobalt molybdenum oxide is capable of forming ions at very acidic and physiological pH conditions, cobalt cations and molybdate anions will be present and completely bioavailable, same as for other soluble cobalt and molybdenum compounds. Due to the existing cobalt and molybdate ions, data from other soluble cobalt and molybdenum substances are used in the derivation of toxicological endpoints for cobalt molybdenum oxide. For further details refer to the analogue justification.
Acute inhalation toxicity
Cobalt substances
There are no available data on acute inhalation toxicity of soluble cobalt substances.
Based on long-term inhalation studies (NTP, 1998; Bucher, 1991) conducted with the surrogate substance cobalt sulfate heptahydrate, there is clear evidence of adverse effects on the respiratory tract (see repeated dose toxicity and carcinogenicity). As cobalt molybdenum oxide contains approx. 67% particles with a particle size below 114 µM and 15% particles with a particle size below 10 µm, there is a potential risk for inhalation exposure.
However, since cobalt molybdenum oxide is classified as carcinogenic via the inhalation route (DSD: Carcinogenicity category 2; R49; CLP: Carcinogenicity category 1B; H350), the test substance is only manufactured and/or used in closed systems under strictly controlled conditions having no risk potential for exposure. In addition, general risk management measures (RMMs) and operational conditions (OCs) including personal protection equipment (PPE) are implemented to avoid the occurrence of human health effects based on the classification as carcinogenic via the inhalation exposure route.
No acute inhalation test was performed due to animal welfare considerations. This is in accordance with Regulation (EC) 1907/2006, which specifies that unnecessary tests should be avoided in terms of animal welfare.
Molybdenum substances
In acute inhalation toxicity studies covering the soluble molybdenum substances disodium molybdate and diammonium dimolybdate and the moderately molybdenum substance molybdenum trioxide, there was a complete absence of mortalities in all studies carried out according to OECD 403 (Leuschner, 2010; Jackson et al., 1991). Correspondingly, the LC50 (4h) for all tested substances was either above the maximum attainable test concentration or above the limit test concentration (> 5 mg/L air).
Acute dermal toxicity
Cobalt substances
There are no available data on acute dermal toxicity of soluble cobalt substances. Data on dermal absorption of soluble cobalt substances indicate that the in-vivo dermal absorption rate in guinea pigs is in the same range as the in-vitro dermal absorption rate reported for humans (Wahlberg, 1965). Based on these data, it was concluded that dermal exposure to cobalt(II)chloride may result in significant systemic uptake of cobalt. However, since cobalt molybdenum oxide is classified as skin sensitizer (DSD: R43; CLP: Category 1; H317), personal protectionmeasures must be applied to avoid skin contact.
No acute dermal test was performed due to animal welfare considerations. This is in accordance with Regulation (EC) 1907/2006, which specifies that unnecessary tests should be avoided in terms of animal welfare.
Molybdenum substances
For the soluble molybdenum substances molybdenum trioxide, disodium molybdate and diammonium dimolybdate, the dermal LD50 was determined to be larger than the limit test dose of 2000 mg/kg bw (Baldrick and Healing, 1990). Soluble molybdate species have a poor rate of dermal absorption (ca. 0.2%).
Justification for classification or non-classification
The available data on acute oral toxicity of the test substance do not meet the criteria for classification according to Regulation (EC) 1272/2008 or Directive 67/548/EEC, and are therefore conclusive but not sufficient for classification.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.